跳至主要内容
临床试验/NCT04828824
NCT04828824招募中4 期

Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial

University of Colorado, Denver1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2021年6月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
600
试验地点
1
主要终点
Implant Continuation

研究概览

简要总结

To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).

详细描述

Objective

To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).

Secondary Objectives:

To determine if participants initiating the contraceptive implant who are also provided COCR are more likely than participants receiving standard counseling to:

  1. report higher levels of satisfaction with their contraceptive implant at one year following initiation
  2. require less clinical follow-up and clinical resources in the year following initiation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
14 Years 至 23 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • You are between ages of 14 to 22.9 years.
  • Started etonogestrel implant for the first time and have never used the implant before.

排除标准

  • There is any contraindication to estrogen containing birth control.
  • Desire of pregnancy in next 12 months.
  • Plans to move from the area in next 12 months and is not able to come to the clinic.

研究组 & 干预措施

COCR Arm

Experimental

Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.

干预措施: Ethinyl Estradiol / Norgestimate Oral Tablet (Drug)

结局指标

主要结局

Implant Continuation

时间窗: 12 months post-insertion

We will assess continuation of use of the contraceptive implant.

次要结局

  • Satisfaction with contraceptive implant(3, 6, and 12 months post-insertion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验